

## EQA round: CSFB2/23 - Cerebrospinal Fluid Analysis

Deadline: 27.11.2023

Setup: groups - R (manufacturer of kit); Slovakia; minimal size of the groups n = 5

RoM = robust average	AV = assigned value	D <sub>max</sub> = acceptable difference
SD = standard deviation	CVP = consensus of all participants	LL = lower limit
CV = coefficient of variation	U <sub>AV</sub> = expanded uncertainty of the assigned value (k = 2)	UL = upper limit
N <sub>tot</sub> = total number of the results		N <sub>eva</sub> = number of the results assessed
N <sub>out</sub> = number of the results removed before calculation		N <sub>suc</sub> = number of successful results
		S <sub>rel</sub> = relative success

Test Sample Group	[unit]	RoM	SD	CV [%]	N <sub>tot</sub>	N <sub>out</sub>	Comparability					N <sub>eva</sub>	N <sub>suc</sub>	S <sub>rel</sub> [%]	
							AV	U <sub>AV</sub>	D <sub>max</sub>	LL	UL				
<b>(333) Albumin</b>	[mg/L]				14							14	14	100	
<b>Sample A</b>		456	26	5,8	14		CVP	444	8,7	23%	341	547	14	14	100
(58) Beckman Coulter (AU)		440	15	3,4	5	0							5		
Other					9	0							9		
							1x 12, 2x 60, 1x 91, 3x 149, 1x 162, 1x 179								
<b>Sample B</b>		184	9	4,9	14		CVP	179	3,3	23%	137	221	14	14	100
(58) Beckman Coulter (AU)		178	3,9	2,2	5	0							5		
Other					9	0							9		
							1x 12, 2x 60, 1x 91, 3x 149, 1x 162, 1x 179								
<b>(330) Total protein</b>	[mg/L]				15								15	15	100
<b>Sample A</b>		703	71	10	15		CVP	693	15	27%	505	881	15	15	100
(58) Beckman Coulter (AU)		766	9,3	1,2	6	0							6		
Other					9	0							9		
							1x 1, 3x 60, 1x 75, 1x 77, 1x 85, 1x 178, 1x 998								
<b>Sample B</b>		295	44	15	15		CVP	297	12	32%	201	393	15	15	100
(58) Beckman Coulter (AU)		336	12	3,7	6	0							6		
Other					9	0							9		
							1x 1, 3x 60, 1x 75, 1x 77, 1x 85, 1x 178, 1x 998								
<b>(331) Glucose</b>	[mmol/L]				15								15	15	100
<b>Sample A</b>		1,8	0,038	2,1	15		CVP	1,79	0,011	18%	1,46	2,12	15	15	100
(58) Beckman Coulter (AU)		1,81	0,03	1,6	7	0							7		
Other					8	0							8		
							3x 46, 3x 60, 1x 75, 1x 188								
<b>Sample B</b>		3,11	0,072	2,3	15		CVP	3,12	0,018	18%	2,55	3,69	15	15	100
(58) Beckman Coulter (AU)		3,13	0,059	1,9	7	0							7		
Other					8	0							8		
							3x 46, 3x 60, 1x 75, 1x 188								
<b>(335) IgA</b>	[mg/L]				4								4	4	100
<b>Sample A</b>					4	0							4	4	100
Other					4	0							4		
							1x 12, 1x 91, 2x 149								
<b>Sample B</b>					4	0							4	4	100
Other					4	0							4		
							1x 12, 1x 91, 2x 149								
<b>(334) IgG</b>	[mg/L]				10								10	9	90
<b>Sample A</b>					10	0							10	10	100
Other					10	0							10		
							1x 12, 1x 58, 1x 60, 2x 91, 4x 149, 1x 162								
<b>Sample B</b>					10	0							10	9	90
Other					10	0							10		
							1x 12, 1x 58, 1x 60, 2x 91, 4x 149, 1x 162								
<b>(336) IgM</b>	[mg/L]				5								5	4	80
<b>Sample A</b>					5	0							5	4	80
Other					5	0							5		
							1x 12, 1x 91, 3x 149								
<b>Sample B</b>					5	0							5	5	100
Other					5	0							5		
							1x 12, 1x 91, 3x 149								
<b>(338) Lactate</b>	[mmol/L]				14								14	14	100
<b>Sample A</b>		7,79	0,32	4,2	14		CVP	7,66	0,073	20%	6,12	9,2	14	14	100
(58) Beckman Coulter (AU)		7,58	0,074	0,98	5	0							5		
Other					9	0							9		
							1x 1, 4x 60, 1x 75, 1x 178, 2x 188								
<b>Sample B</b>		1,98	0,1	5,2	14		CVP	1,99	0,024	20%	1,59	2,39	14	14	100
(58) Beckman Coulter (AU)		1,93	0,022	1,2	5	0							5		
Other					9	0							9		
							1x 1, 4x 60, 1x 75, 1x 178, 2x 188								